FGP
IDXX icon

Freestone Grove Partners’s Idexx Laboratories IDXX Stock Holding History

Freestone Grove Partners’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9M Sell
60,557
-29,959
-33% -$16.8M 0.2% 148
2026
Q1 		$50.9M Buy
+90,516
New +$58M 0.36% 86
2025
Q1 		– Sell
-54,604
Closed -$22.6M – 685
2024
Q4 		$22.6M Buy
+54,604
New +$24M 0.28% 120

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Freestone Grove Partners's IDXX Position: Q2 2026 in Review

Freestone Grove Partners reduced its Idexx Laboratories (IDXX) stake by 33% in Q2 2026, selling an estimated $16.8M and leaving 60,557 shares worth $31.9M. The position accounts for 0.2% of the portfolio, ranked #148.

Freestone Grove Partners first reported a position in IDXX in Q4 2024 and has held it in 3 quarters since. The position peaked at $50.9M in Q1 2026. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Freestone Grove Partners held 60,557 shares of Idexx Laboratories worth $31.9M as of Q2 2026.
  • Freestone Grove Partners sold 29,959 Idexx Laboratories shares in Q2 2026, an estimated $16.8M.
  • Idexx Laboratories made up 0.2% of Freestone Grove Partners's portfolio in Q2 2026, its #148 holding.
  • Freestone Grove Partners first reported a position in Idexx Laboratories in Q4 2024 and has held it in 3 quarters since.
  • Freestone Grove Partners's Idexx Laboratories position peaked at $50.9M in Q1 2026.
  • 1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.